Warning: file_get_contents(http://tehnika-news.ru/shells.txt): failed to open stream: Connection refused in /var/sites/p/paperbomb.com/public_html/meds2/1/index.php on line 2
besponsa 1 mg

besponsa 1 mg

Перейти к контенту

Главное меню:

Разное
besponsa 1 mg
BESPONSA 1 mg powder for concentrate for solution for , Besponsa - FDA prescribing information, side effects and uses, Package leaflet: Information for the user BESPONSA 1 mg , Besponsa 1 mg - pulbere pentru concentrat pentru soluție , Besponsa 1 mg Supplier, Inotuzumab ozogamicin Exporter , Besponsa 1mg - Name Patient Medical Supply Pharmaceutical , , , .
For patient-reported outcomes, most functioning and symptom scores were in favour of BESPONSA compared to Investigator's choice of chemotherapy. Patient-reported outcomes measured using the European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30), were significantly better for BESPONSA by estimated mean postbaseline scores (BESPONSA and Investigator's choice of chemotherapy, respectively) for role functioning (64.7 versus 53.4, improvement grade small), physical functioning (75.0 versus 68.1, improvement grade small), social functioning (68.1 versus 59.8, improvement grade medium), and appetite loss (17.6 versus 26.3, improvement grade small) compared to Investigator's choice of chemotherapy. There was a trend in favour of BESPONSA, improvement grade small, for estimated mean postbaseline scores (BESPONSA and Investigator's choice, respectively) in global health status/Quality of Life (QoL) (62.1 versus 57.8), cognitive functioning (85.3 versus 82.5), dyspnoea (14.7 versus 19.4), diarrhoea (5.9 versus 8.9), fatigue (35.0 versus 39.4). There was a trend in favour of BESPONSA for estimated mean postbaseline scores from the EuroQoL 5 Dimension (EQ-5D) questionnaire, (BESPONSA and Investigator's choice of chemotherapy, respectively) for the EQ-5D index (0.80 versus 0.76, minimally important difference for cancer = 0.06).. For the first cycle, the recommended total dose of BESPONSA for all patients is 1.8 mg/m2 per cycle, given as 3 divided doses on Days 1 (0.8 mg/m2), 8 (0.5 mg/m2), and 15 (0.5 mg/m2). Cycle 1 is 3 weeks in duration, but may be extended to 4 weeks if the patient achieves a CR or CRi, and/or to allow recovery from toxicity.. In patients who achieve a CR or CRi, the recommended total dose of Besponsa is 1.5 mg/m 2 per cycle, administered as 3 divided doses on Day 1 (0.5 mg/m 2), Day 8 (0.5 mg/m 2), and Day 15 (0.5 mg/m 2). Subsequent cycles are 4 weeks in duration. OR.
Page 1 of 10 Package leaflet: Information for the user BESPONSA 1 mg powder for concentrate for solution for infusion inotuzumab ozogamicin. 1. Denumire, compoziţie şi clasa de medicamente din care face parte. Besponsa 1 mg conţine substanţa activă numită inotuzumab ozogamicin (1 mg) ce face parte din categoria medicamentelor antineoplazice (utilizate în tratamentul cancerelor).. Description. Besponsa is a prescription drug, it is an anti-body conjugate used to treat refractory B-cell precursor acute lymphoblastic leukemia.. The dynamic ingredient in BESPONSA is inotuzumab ozogamicin. This belongs to a group of drugs or medicines that objective cancer cells. These drugs are called antineoplastic agents. BESPONSA is utilized to treat adults with intense lymphoblastic leukaemia. Acute lymphoblastic leukaemia is a cancer of blood where you have too many white cells.. . .
 
Copyright 2019. All rights reserved.
Назад к содержимому | Назад к главному меню